Original Article
Copyright ©2014 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastrointest Oncol. Jan 15, 2014; 6(1): 22-33
Published online Jan 15, 2014. doi: 10.4251/wjgo.v6.i1.22
Novel blood-based microRNA biomarker panel for early diagnosis of pancreatic cancer
Ganepola AP Ganepola, John R Rutledge, Paritosh Suman, Anusak Yiengpruksawan, David H Chang
Ganepola AP Ganepola, John R Rutledge, Paritosh Suman, David H Chang, Center for Cancer Research and Genomic Medicine, The Valley Hospital, Paramus, NJ 07652, United States
Ganepola AP Ganepola, Anusak Yiengpruksawan, Department of Surgery, The Valley Hospital, Ridgewood, NJ 07450, United States
Supported by The Valley Hospital Foundation Research Fund and private donations
Author contributions: Ganepola GAP, Suman P, Yiengprukswan A and Chang DH designed the research; Ganepola GAP and Chang DH performed the experiments; Ganepola GAP, Chang DH and Rutledge JR analyzed the data and wrote the manuscript.
Correspondence to: David H Chang, PhD, Research Scientist, Center for Cancer Research and Genomic Medicine, The Daniel and Gloria Blumenthal Cancer Center, The Valley Hospital, 1 Valley Health Plaza, Paramus, NJ 07652, United States. davidhc9@gmail.com
Telephone: +1-201-6345542 Fax: +1-201-6345383
Received: August 22, 2013
Revised: December 5, 2013
Accepted: December 12, 2013
Published online: January 15, 2014
Core Tip

Core tip: This study employed high throughput screening as a screening tool to identify blood-based circulating microRNA markers for detection of early stage pancreatic cancer. Two levels of confirmation were performed to ensure the validity of the identified microRNA targets. First, a panel of potential microRNA markers was generated and confirmed using a more specific and sensitive secondary assay, real-time quantitative reverse transcription polymerase chain reaction. Second, the confirmed panel of microRNA markers was independently validated with different experimental procedures and instruments, by independent personnel, and at a different institution, to diagnose a new cohort of patients and controls.